Search research articles
Contact Us
Filters
Showing results (201-210 of 265) with videos related to
Page
of 27
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
February 22, 2020
Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy
Alan Pollack, Felix M Chinea, Elizabeth Bossart, et al.
The Prostate
|
April 20, 2012
Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer
Michael G Heckman, Alexander S Parker, Kevin J Wu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 17, 2018
An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes
Radka Stoyanova, Felix Chinea, Deukwoo Kwon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, et al.
Cancers
|
September 23, 2022
Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
Ahmad Algohary, Mohammad Alhusseini, Adrian L Breto, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2022
Clinicogenomic characterization of prostate cancer liver metastases
Mohammed Alshalalfa, Crystal Seldon, Idalid Franco, et al.
The Lancet. Oncology
|
September 21, 2007
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial
Li-Yan Khor, Kyounghwa Bae, Alan Pollack, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 26, 2005
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
Alan Pollack, Alexandra L Hanlon, Eric M Horwitz, et al.
Oncotarget
|
April 23, 2019
Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors
N Andres Parra, Hong Lu, Qian Li, et al.
Oncotarget
|
January 17, 2019
Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors
N Andres Parra, Hong Lu, Qian Li, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 265) with videos related to
Sort By:
Page
of 27
International Journal of Radiation Oncology, Biology, Physics
|
February 22, 2020
Phase I Trial of MRI-Guided Prostate Cancer Lattice Extreme Ablative Dose (LEAD) Boost Radiation Therapy
Alan Pollack, Felix M Chinea, Elizabeth Bossart, et al.
The Prostate
|
April 20, 2012
Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer
Michael G Heckman, Alexander S Parker, Kevin J Wu, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 17, 2018
An Automated Multiparametric MRI Quantitative Imaging Prostate Habitat Risk Scoring System for Defining External Beam Radiation Therapy Boost Volumes
Radka Stoyanova, Felix Chinea, Deukwoo Kwon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, et al.
Cancers
|
September 23, 2022
Longitudinal Changes and Predictive Value of Multiparametric MRI Features for Prostate Cancer Patients Treated with MRI-Guided Lattice Extreme Ablative Dose (LEAD) Boost Radiotherapy
Ahmad Algohary, Mohammad Alhusseini, Adrian L Breto, et al.
Prostate Cancer and Prostatic Diseases
|
January 13, 2022
Clinicogenomic characterization of prostate cancer liver metastases
Mohammed Alshalalfa, Crystal Seldon, Idalid Franco, et al.
The Lancet. Oncology
|
September 21, 2007
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial
Li-Yan Khor, Kyounghwa Bae, Alan Pollack, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 26, 2005
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
Alan Pollack, Alexandra L Hanlon, Eric M Horwitz, et al.
Oncotarget
|
April 23, 2019
Erratum: Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors
N Andres Parra, Hong Lu, Qian Li, et al.
Oncotarget
|
January 17, 2019
Predicting clinically significant prostate cancer using DCE-MRI habitat descriptors
N Andres Parra, Hong Lu, Qian Li, et al.
Page
of 27